Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non Small Cell Lung Cancer ALK Positive or ROS1 Positive”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Not applicableNo Longer AvailableNCT03178071
What this trial is testing

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Who this might be right for
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
Not applicableNot Yet RecruitingNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT05765877
What this trial is testing

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer(NSCLC)
Pingping Song 26
Testing effectiveness (Phase 2)Study completedNCT01945021
What this trial is testing

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerROS1 Proto OncogeneCrizotinib
Pfizer 129
Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Testing effectiveness (Phase 2)Looking for participantsNCT04237805
What this trial is testing

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Advanced CancerAdvanced Solid TumorLung Cancer, Nonsmall Cell
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 280
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Early research (Phase 1)Active Not RecruitingNCT05441956
What this trial is testing

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Shenzhen TargetRx, Inc. 198
Testing effectiveness (Phase 2)Study completedNCT03088930
What this trial is testing

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Nonsmall Cell
University of Colorado, Denver 3
Testing effectiveness (Phase 2)UnknownNCT04641754
What this trial is testing

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 176
Post-approval studies (Phase 4)Ended earlyNCT03672643
What this trial is testing

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Who this might be right for
ALK or ROS1-positive NSCLC
Pfizer 41
Early research (Phase 1)Study completedNCT03420742
What this trial is testing

Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Who this might be right for
Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
Takeda 24
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37